Please login to the form below

Not currently logged in
Email:
Password:

Pfizer tries to quash Trovan report in Nigeria

Pfizer initiates legal action in Nigerian Federal high court to quash a report by the Investigating Committee on Trovan

Pfizer has initiated a legal action in the Abuja division of the Nigerian Federal high court to quash a report by the Investigating Committee on the Trovan (trovafloxacin) clinical trial conducted in Kano state in 1996.

The government had charged Pfizer and eight others with alleged criminal application of trovafloxacin on 200 Nigerian children. The trial, it is alleged, killed many of the children and left others with various permanent disabilities.

The new Pfizer suit has demanded an order of certiorari (a type of writ seeking judicial review) and the action was assigned to Justice Anwuri Chikere for trial.

If successful, the certiorari could nullify the multiple criminal and civil actions against Pfizer Nigeria and individuals Isa Dutse, Scott Hopkins, Debra Williams, Mike Dunne, Samuel Ohuabunwa, Robert Buhl and William Steere, all of whom face a total 23-count charge.

The high court judge had granted Pfizer an extension of time to apply for leave to challenge the report. The accused could not be arraigned as they were not in court at the last adjourned date.

31st July 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics